Compounds > imatinib

Page last updated: 2024-08-16

imatinib and vx680

imatinib has been researched along with vx680 in 14 studies

Research

Studies (14)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (42.86)	29.6817
2010's	7 (50.00)	24.3611
2020's	1 (7.14)	2.80

Authors

Authors	Studies
Atteridge, CE; Biggs, WH; Carter, TA; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Grotzfeld, RM; Herrgard, S; Insko, DE; Lockhart, DJ; Mehta, SA; Milanov, ZV; Pao, W; Patel, HK; Sawyers, CL; Shah, NP; Treiber, DK; Varmus, H; Velasco, AM; Wodicka, LM; Zarrinkar, PP	1
Giranda, VL; Johnson, EF; Luo, Y; Stewart, KD; Woods, KW	1
Dalgarno, D; Keats, J; Lamore, S; Li, F; Parillon, L; Shakespeare, W; Wang, Y; Xu, Q; Zhou, T; Zhu, X	1
Archibald, H; Dowell, L; Drew, L; Erlander, MG; Gray, NS; Greninger, P; Haber, DA; Hanke, JH; Iafrate, AJ; Lamb, J; Lee, D; Ma, XJ; Maheswaran, S; McDermott, U; Montagut, C; Njauw, CN; Raudales, R; Rothenberg, SM; Settleman, J; Sharma, SV; Sordella, R; Supko, JG; Tam, A; Tsao, H; Ulkus, LE	1
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP	1
Bignell, CR; Cherry, M; Chu, ML; Eyers, PA; Scutt, PJ; Sloane, DA; Williams, DH	1
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB	1
Russu, WA; Shallal, HM	1
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP	1
Chen, SP; Cui, J; Fu, R; Li, GW; Liu, S; Qian, SX; Zhou, LH	1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ	1
Cahya, S; Cummins, DJ; Gao, C; Iversen, PW; Nicolaou, CA; Vieth, M; Wang, J; Watson, IA	1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP	1
Hao, RR; Huang, WH; Liang, MH; Pan, YL; Shen, ZR; Zeng, SX	1

Reviews

1 review(s) available for imatinib and vx680

Article	Year
The progress of small-molecules and degraders against BCR-ABL for the treatment of CML. European journal of medicinal chemistry, 2022, Aug-05, Volume: 238 Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2022

Other Studies

13 other study(ies) available for imatinib and vx680

Article	Year
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proceedings of the National Academy of Sciences of the United States of America, 2005, Aug-02, Volume: 102, Issue:31 Topics: Aminoquinolines; Aniline Compounds; Cell Line; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Indoles; Kinetics; Morpholines; Mutation; Naphthalenes; Neoplasms; Oncogene Proteins v-abl; Organic Chemicals; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrroles; Sunitinib	2005
Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity. Biochemistry, 2007, Aug-21, Volume: 46, Issue:33 Topics: Adenosine Triphosphate; Amino Acid Sequence; Androstadienes; Binding Sites; Cell Cycle Proteins; Humans; Models, Molecular; Molecular Sequence Data; Peptide Library; Polo-Like Kinase 1; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Substrate Specificity; Wortmannin	2007
Crystal structure of the T315I mutant of AbI kinase. Chemical biology & drug design, 2007, Volume: 70, Issue:3 Topics: Animals; Cell Line; Crystallography, X-Ray; Mice; Models, Molecular; Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-abl; Pyridines; Structural Homology, Protein; Threonine	2007
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-11, Volume: 104, Issue:50 Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Genotype; Humans; Neoplasms; Protein Kinase Inhibitors	2007
A quantitative analysis of kinase inhibitor selectivity. Nature biotechnology, 2008, Volume: 26, Issue:1 Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship	2008
Discovery and exploitation of inhibitor-resistant aurora and polo kinase mutants for the analysis of mitotic networks. The Journal of biological chemistry, 2009, Jun-05, Volume: 284, Issue:23 Topics: Aurora Kinase B; Aurora Kinases; Benzamides; Binding Sites; DNA Mutational Analysis; DNA, Complementary; Enzyme Inhibitors; Humans; Imatinib Mesylate; Kinetics; Mitosis; Mutagenesis; Piperazines; Protein Serine-Threonine Kinases; Pyrimidines	2009
Navigating the kinome. Nature chemical biology, 2011, Volume: 7, Issue:4 Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology	2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives. European journal of medicinal chemistry, 2011, Volume: 46, Issue:6 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship	2011
Comprehensive analysis of kinase inhibitor selectivity. Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11 Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity	2011
BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives. Bioorganic & medicinal chemistry letters, 2013, Apr-15, Volume: 23, Issue:8 Topics: Drug Design; Fusion Proteins, bcr-abl; Models, Molecular; Protein Kinase Inhibitors; Pyrimidines; Quantitative Structure-Activity Relationship	2013
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15 Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship	2013
Selectivity data: assessment, predictions, concordance, and implications. Journal of medicinal chemistry, 2013, Sep-12, Volume: 56, Issue:17 Topics: Computer Simulation; Drug Discovery	2013
The target landscape of clinical kinase drugs. Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays	2017

chemdatabank.com